References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
- Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v78–v84.
- Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980–988.
- Robak T, Stilgenbauer S, Tedeschi A. Front-line treatment of CLL in the era of novel agents. Cancer Treat Rev. 2017 Feb;53:70–78.
- Byrd JC, Furman RR, Coutre SE, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
- Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–1109.
- Davids M, Kim H, Brander D, et al. Initial results of a multicenter, phase II study of ibrutinib plus FCR (iFCR) as frontline therapy for younger CLL patients. Blood. 2016;128:3243. Abstract.
- Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma: a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
- Fraser G, Cramer P, Demirkan F, et al. Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. J Clin Oncol. 2016;34(Suppl):Abstract 7525.
- Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–1817.
- Herman SE, Niemann CU, Farooqui M, et al. Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia. 2014;28:2188–2196.
- Jones JA, Robak T, Brown JR, et al. Results of a phase 3 randomised, controlled study evaluating the efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia. Lancet Hematol. 2017;4:e114–e126.
- Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib in combination with bendamustine and rituximab improves overall survival in patients with relapsed/refractory CLL – interim results of a phase 3 randomized placebo-controlled trial. Lancet Oncol. 2017;18:297–311.
- Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–322.
- Jones J, Choi MY, Mato, et al. Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. Blood. 2016;128(Abstract):637.
- Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125:2062–2067.
- Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
- Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18:230–240.
- Thompson M, Brander D, Nabhan C, et al. Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents: a review. JAMA Oncol. 2017 Jul 27. DOI:10.1001/jamaoncol.2017.2009
- Thompson PA, Tam CS, O’Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–309.
- Flinn I, Moreno C, Gill DS, et al. Randomized, multicenter, open-label, phase 3 study of the BTK inhibitor ibrutinib in combination with obinutuzumab vs. chlorambucil in combination with obinutuzumab in patients with treatment-naïve CLL/SLL (PCYC- 1130): iLLUMINATE. J Clin Oncol. 2015;33(suppl):Abstract TPS7095.